Acquired Company
Roche acquired 89bio, Inc. at $14.50 per share in cash plus a contingent value right (CVR) of up to $6.00 per share, for a total equity value of up to approximately $3.5 billion, with closing expected in the fourth quarter of 2025.
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly known as The company was founded in 2018 and is based in San Francisco, California. As of October 29, 2025, 89bio, Inc. operates as a subsidiary of Roche Holding AG. Show more
Location: 655 Montgomery Street, San Francisco, CA, 94111, United States | Website: https://www.89bio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
2.204B
52 Wk Range
$4.16 - $15.06
Previous Close
$14.84
Open
$14.84
Volume
N/A
Day Range
$14.84 - $14.84
Enterprise Value
1.68B
Cash
561.2M
Avg Qtr Burn
-109.8M
Insider Ownership
0.60%
Institutional Own.
-
Qtr Updated
06/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Pegozafermin (BIO89-100) (FGF21 analog) Details metabolic dysfunction-associated steatohepatitis | Phase 3 Data readout | |
Pegozafermin (BIO89-100) (FGF21 analog) Details Non-alcoholic steatohepatitis | Phase 3 Update | |
Pegozafermin (BIO89-100) (FGF21 analog) Details Severe hypertriglyceridemia | Phase 3 Update |